L-[1-13C] phenylalanine oxidation as a measure of hepatocyte functional capacity in end-stage liver disease

Burke, Patricia A.; Stack, Jennifer A.; Wagner, David; Lewis, David W.; Jenkins, Roger L.; Forse, R. Armour

doi:10.1016/s0002-9610(96)00392-3

Cited by 51 publications

(60 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…between Controls and ChPA, ChPA and ChPB and ChPB and ChPC, respectively, were calculated. This finding, which is in agreement with some studies 31,32,15 but not others 33 , is of practical importance, since it suggests that further (up to 20 min) breath samples are not necessary. An exception found was in the discrimination between healthy controls and patients with nonsymptomatic cirrhosis (Child-Pugh A classification), which occurred at the 80 th minute of PDR (the exception was based on the ROC analysis).…”

Section: Discussionsupporting

confidence: 92%

13C-methacetin breath test in the evaluation of disease severity in patients with liver cirrhosis

Vranová¹,

Hendrichová²,

Kolářová³

et al. 2013

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Aims. The non-invasive 13 C-methacetin ( 13 C-MBT) breath test has been proposed as a measure of metabolic liver function that improves the diagnostic efficacy of serologic and biochemical tests in assessing hepatic functional capacity and liver disease severity, The goal of this study was to establish the clinical utility of this test in quantifying hepatic metabolic function in patients with liver cirrhosis of varying severity and to compare 13 C-MBT measurements with the AST/ALT ratio, APRI score, and other routine liver tests. Methods. Routine liver function tests including serum bilirubin, aspartate aminotransferase activity (AST), alanine aminotransferase (ALT), AST/ALT ratio, the APRI score, the percentage of dose rate (PDR) and cumulative percentage of dose rate (CPDR) of the 13 C-MBT were evaluated in 52 cirrhotic patients of alcohol etiology (Child-Pugh A/B/C 10/28/14) and 37 healthy controls. Results. The 13 C-MBT differed significantly between healthy controls and cirrhotic patients at all time intervals measured. It also proved the ability to differentiate patients with liver cirrhosis based on severity of hepatic impairment corresponding to the Child-Pugh classification A vs. B vs. C. The ROC curve analysis suggested that the best prediction is provided by time intervals between the 10 th -20 th or 10 th -40 th minute of PDR. Conclusions. The 13 C-MBT offers a reliable means for quantification of hepatic metabolic function over the complete range of functional liver impairment. It is non-invasive, easy to perform and completely safe.

show abstract

Section: Discussionsupporting

confidence: 92%

13C-methacetin breath test in the evaluation of disease severity in patients with liver cirrhosis

Vranová¹,

Hendrichová²,

Kolářová³

et al. 2013

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

show abstract

“…Therefore, it is important to assess accurately the hepatocyte functional capacity in patients. As reported by Burke et al, 13 C-PheBT shows a correlation with Child Pugh classification, 15) reflecting its ability to predict hepatocyte functional capacity. 13 C-PheBT may be capable of predicting mortality after hepatic resection for hepatocellular carcinoma.…”

Section: Resultsmentioning

confidence: 52%

“…15) In our study, patients with cirrhosis were classified by their score in 13 C-PheBT into either class B (nϭ10) or class C (nϭ3). The % 13 C cumulative dose of patients classified into class B was 4.9Ϯ0.7, and that of class C was 2.2Ϯ1.0.…”

Section: Resultsmentioning

confidence: 99%

Evaluation of 13C-Phenylalanine and 13C-Tyrosine Breath Tests for the Measurement of Hepatocyte Functional Capacity in Patients with Liver Cirrhosis.

et al. 2001

View full text Add to dashboard Cite

show abstract

“…Burke et al [3]have shown decreased 13 CO 2 in the breath of patients with end-stage liver disease during the [1- 13 C]-phenylalanine breath test. Here, we also demonstrated that not only in end-stage liver disease, but also in galactosamine hepatitis rats [8, 9], which show less severe signs of liver failure compared to end-stage liver disease, Δ 13 CO 2 (‰) in the [1- 13 C]-phenylalanine breath test was decreased.…”

Section: Discussionmentioning

confidence: 99%

“…Burke et al [3]showed that 13 CO 2 was decreased in patients with end-stage liver disease by use of the [1- 13 C]-phenylalanine breath test. They reported that expired 13 CO 2 in patients with end-stage liver disease was less than 1/5 of that in control subjects.…”

Section: Introductionmentioning

confidence: 99%

High Correlation between Results of the [1-13C]-Phenylalanine Breath Test and Phenylalanine Hydroxylase (EC 1.14.16.1) Activity of the Liver in Rats

Ito

Kohno²,

Hosoi³

et al. 2001

Digestion

View full text Add to dashboard Cite

Background:¹³CO₂ is decreased in patients with end-stage liver disease by the [1-¹³C]-phenylalanine breath test. Decreased ¹³CO₂ is supposed to be caused by the decreased ability of the liver to oxidize phenylalanine. However, no direct evidence has been reported. Methods: The [1-¹³C]-phenylalanine breath test was performed in galactosamine hepatitis rats (n = 14) and control rats (n = 8). Plasma phenylalanine concentration before intravenous administration of [1-¹³C]-phenylalanine, the elimination rate of phenylalanine and the phenylalanine hydroxylase (PAH; EC 1.14.16.1) activity of the whole liver were examined. Results: Increase of ¹³CO₂ in the breath [Δ¹³CO₂ (‰)] of galactosamine hepatitis rats 2 min after administration of [1-¹³C]-phenylalanine was only 1/5 of that in control rats. The concentration of plasma phenylalanine and the elimination rate of plasma phenylalanine in hepatitis rats did not show significant differences compared to control rats. On the other hand, a clear difference in the activity of PAH was observed between hepatitis rats and control rats. Δ¹³CO₂ (‰) 2 min after administration of [1-¹³C]-phenylalanine was highly correlated to the PAH activity of the whole liver (r = 0.917). Conclusion: It was strongly indicated that decreased Δ¹³CO₂ in hepatitis rats was the result of decreased activity of PAH.

show abstract

L-[1-13C] phenylalanine oxidation as a measure of hepatocyte functional capacity in end-stage liver disease

Cited by 51 publications

References 22 publications

<sup>13</sup>C-methacetin breath test in the evaluation of disease severity in patients with liver cirrhosis

<sup>13</sup>C-methacetin breath test in the evaluation of disease severity in patients with liver cirrhosis

Evaluation of 13C-Phenylalanine and 13C-Tyrosine Breath Tests for the Measurement of Hepatocyte Functional Capacity in Patients with Liver Cirrhosis.

High Correlation between Results of the [1-<sup>13</sup>C]-Phenylalanine Breath Test and Phenylalanine Hydroxylase (EC 1.14.16.1) Activity of the Liver in Rats

Contact Info

Product

Resources

About